Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma

Inclusion Criteria: * Patients with resectable pancreatic adenocarcinoma * Age over 18 years old and younger than 70 year old * Performance status (ECOG scale): 0-1 * Adequate organ functions * Hb ≥9.0 g/dl * ANC ≥1,500/mm3 * PLT ≥100,000/mm3 * Liver function: Total Bilirubin ≤3.0 mg/dl AST/ALT/ALP ≤3× upper limit of normal * Creatinine ≤1.5 ULN * Patients should sign a written informed consent before study entry. Exclusion Criteria: * Tumor type other than adenocarcinoma * Unresectable for resection on preoperative evaluation * Other primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence) * Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) * Prior radiotherapy * Major surgery within 4 weeks prior to study treatment * Serious illness or medical conditions, as follows; * congestive heart failure (NYHA class III or IV) * unstable angina or myocardial infarction within the past 6 months, * significant arrhythmias requiring medication and conduction abnormality such as over 2nd degree AV block * uncontrolled hypertension * hepatic cirrhosis( ≥ Child class B) * interstitial pneumonia, pulmonary adenomatosis * psychiatric disorder that may interfere with and/or protocol compliance * unstable diabetes mellitus * uncontrolled ascites or pleural effusion * active infection * Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug * Pregnant or lactating woman * Women of child bearing potential not using a contraceptive method * Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential * Any patients judged by the investigator to be unfit to participate in the study